West Pharmaceutical Services urges industry to adapt as USP draft chapters reshape contamination control

West Pharmaceutical Services urges industry to adapt as USP draft chapters reshape contamination control
USP drafts reshape contamination control

West Pharmaceutical Services is urging stakeholders in the pharmaceutical sector to update contamination control strategies, as the United States Pharmacopeia (USP) releases draft chapters 1110 and 1114.

These drafts introduce the next era of risk-based contamination control strategies (CCS), signaling substantial changes in regulatory expectations. Industry participants are encouraged to review their current protocols to remain compliant and competitive as new guidelines emerge.

The sector's response to evolving regulatory standards will likely influence not only compliance but also future recognition for excellence, as demonstrated by West Pharmaceutical Services' achievements in securing top supplier and innovation awards in drug delivery. In addition, collaborative industry engagement, reminiscent of West's recent initiatives to connect with experts at the BIO China event, may prove essential in navigating the transition to these updated contamination control protocols.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.